Breast Cancer
Conditions
Brief summary
This is an Asia-Pacific regional, randomized, double-blind, multicenter trial designed to evaluate treatment with trastuzumab + pertuzumab + docetaxel compared with trastuzumab + placebo + docetaxel in chemotherapy-naïve participants with early-stage or locally advanced HER2-positive breast cancer. The anticipated treatment duration is approximately 17 months.
Interventions
DRUGFEC Chemotherapy
Fluorouracil 500-600 milligrams per square meter (mg/m2), epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by intravenous (IV) infusion every 3 weeks for three cycles (Cycles 5-7). FEC chemotherapeutic agents will be administered following surgery on Day 1 of each specified cycle.
PROCEDURESurgery
All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
DRUGDocetaxel
Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4.
DRUGPertuzumab
Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4. After surgery and 3 cycles of FEC chemotherapy (adjuvant treatment): 840 mg loading dose for Cycle 8, followed by 420 mg for Cycles 9-20)
DRUGPlacebo
Placebo by IV infusion in 3-week cycles as neoadjuvant treatment (Cycles 1-4)and as adjuvant treatment (Cycles 8-20)
DRUGTrastuzumab
Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 8, followed by 6 mg/kg for Cycles 9-20.
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed invasive breast carcinoma with a primary tumor size of more than (\>) 2 centimeters (cm) by standard local assessment technique * Breast cancer stage at presentation: early-stage (T2-3, N0-1, M0) or locally advanced (T2-3, N2 or N3, M0; T4, any N, M0) * HER2-positive breast cancer confirmed by a Sponsor-designated central laboratory and defined as 3+ score by immunohistochemistry in \> 10 percent (%) of immunoreactive cells or HER2 gene amplification (ratio of HER2 gene signals to centromere 17 signals equal to or more than \[\>=\] 2.0) by in situ hybridization * Known hormone receptor status (estrogen receptor and/or progesterone receptor) * Eastern Cooperative Oncology Group Performance Status equal to or less than (\<=) 1 * Baseline left ventricular ejection fracture \>= 55% measured by echocardiography (preferred) or multiple gated acquisition scan * Negative serum pregnancy test
Exclusion criteria
* Stage IV metastatic breast cancer * Inflammatory breast cancer * Previous anti-cancer therapy or radiotherapy for any malignancy * History of other malignancy within 5 years prior to screening, except for appropriately-treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer * Concurrent anti-cancer treatment in another investigational trial, including hormone therapy, bisphosphonate therapy, or immunotherapy * Major surgical procedure unrelated to breast cancer within 4 weeks prior to randomization or from which the participant has not fully recovered * Serious cardiac illness or medical condition * Other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness * Any abnormalities in liver, kidney or hematologic function laboratory tests immediately prior to randomization * Sensitivity to any of the study medications, any of the ingredients or excipients of these medications, or benzyl alcohol * Pregnant or lactating
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC) | At surgery (Cycle 4 Days 22-35) | This tpCR was assessed by the IRC. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes after completion of neoadjuvant therapy and surgery (that is, ypT0/is, ypN0, in accordance with the current American Joint Committee on Cancer \[AJCC\] staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose tpCR assessment was missing or invalid were counted as not achieving tpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With tpCR as Assessed by the Local Pathologist | At surgery (Cycle 4 Days 22-35) | This tpCR was assessed by the local pathologist. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes after completion of neoadjuvant therapy and surgery (that is, ypT0/is, ypN0, in accordance with the current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose tpCR assessment was missing or invalid were counted as not achieving tpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point. |
| Percentage of Participants With Breast Pathologic Complete Response (bpCR), Defined as ypT0/is According to the AJCC Staging System as Assessed by the IRC | At surgery (Cycle 4 Days 22-35) | This bpCR was assessed by the IRC. bpCR was defined as the absence of any residual invasive cancer on the hematoxylin and eosin evaluation of the resected breast specimen after completion of neoadjuvant therapy and surgery (that is, ypT0/is, in accordance with current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose bpCR assessment was missing or invalid were counted as not achieving bpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point. |
| Percentage of Participants With bpCR as Assessed by the Local Pathologist | At surgery (Cycle 4 Days 22-35) | This bpCR was assessed by the local pathologist. bpCR was defined as the absence of any residual invasive cancer on the hematoxylin and eosin evaluation of the resected breast specimen after completion of neoadjuvant therapy and surgery (that is, ypT0/is in accordance with current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose bpCR assessment was missing or invalid were counted as not achieving bpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point. |
| Percentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | At surgery (Cycle 4 Days 22-35) | Clinical responses that include percentage of participants with a CR, PR, SD, or PD were determined by investigator during Cycles 1-4 (prior to surgery) on basis of RECIST version 1.1. CR=disappearance of all target lesions i.e., any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum during the study. PD=at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (nadir) with inclusion of baseline. Only participants with measurable disease at baseline were included in the analysis. 1 Cycle=21 days. The percentages have been rounded off to first decimal point. |
| Percentage of Participants With an Objective Response (CR or PR) During Cycles 1-4, According to RECIST Version 1.1 | At surgery (Cycle 4 Days 22-35) | An objective response was defined as the percentage of participants who achieved a CR or PR as the best tumor response during the neoadjuvant period (that is, during Cycles 1-4 prior to surgery), as determined by the investigator on the basis of RECIST version 1.1. CR=disappearance of all target lesions i.e., any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. No confirmation was required for objective response. Only participants with measurable disease at baseline were included in the analysis. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point. |
| Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Event-Free Survival (EFS) at 1, 3, and 5 Years | From Baseline to EFS event or date last known to be alive and event-free at 1, 3, and 5 years | Kaplan-Meier approach was used to estimate percentage of participants who were event-free for EFS at 1, 3 & 5 years. EFS=time from randomization to first documentation of one of the following events: PD (before surgery) as determined by investigator with RECIST v1.1. PD=at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum during the study (nadir) with inclusion of baseline. Any evidence of contralateral disease in situ was not identified as PD; Disease recurrence (local, regional, distant, or contralateral) after surgery; Death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year & then every 6 months thereafter, until disease progression/recurrence or until 5 years after randomization of last participant, whichever occurred first. Participants without an EFS event at time of analysis were censored as of the date they were last known to be alive & event-free. |
| Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Disease-Free Survival (DFS) at 1, 3, and 5 Years | From surgery (Cycle 4: Days 22-35) to DFS event or date last known to be alive and event-free at 1, 3, and 5 years | Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for DFS at 1, 3 and 5 years. DFS = time from first date of no disease (i.e., date of surgery) to first documentation of one of the following events: Disease recurrence (local, regional, distant, or contralateral) after surgery or death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year and then every 6 months thereafter, until disease progression or recurrence or until 5 years after randomization of the last participant, whichever occurred first. Participants were considered to be disease-free if they underwent surgery and no recurrence of disease was reported thereafter. Data from participants who did not have an event at analysis were censored as of the date they were last known to be alive and event-free. |
| Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1, 3, and 5 Years | From Baseline to OS event or date last known to be alive at 1, 3, and 5 years | Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for OS at 1, 3 and 5 years. OS was defined as the time from randomization to death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year and then every 6 months thereafter, until disease progression or recurrence or until 5 years after randomization of the last participant, whichever occurred first. Data from participants who were alive at the time of the analysis was censored as of the last date they were known to be alive. |
| Percentage of Participants With at Least One Adverse Event (AE) During the Neoadjuvant Treatment Period | Baseline up to end of Cycle 4 (1 cycle = 21 days) | The percentage of participants who experienced at least one AE during the neoadjuvant period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. The neoadjuvant treatment period began after randomization upon receiving the first dose of any of the neoadjuvant study medications and ended before receiving the first dose of adjuvant study treatment. The duration of one treatment cycle is 21 days. The percentages have been rounded off to first decimal point. |
| Percentage of Participants With at Least One AE During the Adjuvant Treatment Period | From Cycle 5 (1 cycle = 21 days) up to 42 days after the last dose in Cycle 20 Day 1 (approximately 1 year) | Percentage of participants who experienced at least one adverse event during the adjuvant period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. Adjuvant treatment period began after primary surgery, upon receiving the first dose of any of the adjuvant study medications. It ended 42 days after last dose of adjuvant study treatment upon treatment completion or discontinuation. 1 Cycle=21 days. The percentages have been rounded off to first decimal point. |
| Percentage of Participants With at Least One Adverse Event During the Treatment-Free Follow-Up Period | From end of overall study treatment until disease progression or until 5 years after randomization of the last patient, whichever occurred first (up to 6 years) | The percentage of participants who experienced at least one adverse event during the treatment-free follow-up period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. The percentages have been rounded off to first decimal point. |
| Percentage of Participants Who Experienced a Primary Cardiac Event | From Baseline until end of study (up to 6 years) | A primary cardiac event is defined as heart failure (New York Heart Association \[NYHA\] Class III or NYHA Class IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction points from baseline and to below 50%. |
| Percentage of Participants Who Experienced a Secondary Cardiac Event | From Baseline until end of study (up to 6 years) | A secondary cardiac event is defined as an asymptomatic or mildly symptomatic (NYHA Class II) drop in LVEF by multiple-gated acquisition (MUGA) scan or echocardiogram confirmed by a second LVEF assessment within approximately 3 weeks showing also a documented drop. A significant LVEF drop is defined as an absolute decrease of at least 10 points below the baseline measurement and to below 50%. |
| Maximum Change From Baseline in LVEF | Baseline; Day 1 of Cycles 2, 4, 5, 8, 11, and 20 (1 cycle = 21 days) | LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram (preferred) or MUGA scan. The same method was used throughout the study for each participant and preferably performed and evaluated by the same assessor. Here, we report the maximum change from baseline in LVEF at any point during the study. |
| Change From Baseline in LVEF Over Time | Baseline; Day 1 of Cycles 2, 4, 5, 8, 11, and 20 (1 cycle = 21 days) | LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram (preferred) or MUGA scan. The same method was used throughout the study for each participant and preferably performed and evaluated by the same assessor. Here, we report the change from baseline in LVEF over time. |
Countries
China, South Korea, Taiwan, Thailand
Participant flow
Recruitment details
A total of 329 participants with early-stage or locally advanced human epidermal growth factor receptor (HER) 2-positive breast cancer were enrolled in this study at 23 investigative sites in China, Republic of Korea, Taiwan, and Thailand from 14 March 2016 to 14 March 2022.
Participants by arm
| Arm | Count |
|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, pertuzumab, 840 mg loading dose in Cycle 1, followed by 420 mg from Cycles 2-4, and docetaxel, 75 mg/m\^2 from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\^2, epirubicin 90-120 mg/m\^2, and cyclophosphamide 500-600 mg/m\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and pertuzumab, 840 mg loading dose in Cycle 8, followed by 420 mg from Cycles 9-20 (1 cycle = 21 days). | 219 |
| Placebo, Trastuzumab, and Chemotherapy Prior to surgery: Participants received trastuzumab, 8 mg/kg loading dose in Cycle 1, followed by 6 mg/kg from Cycles 2-4, docetaxel, 75 mg/m\^2 and placebo from Cycles 1-4 (1 cycle = 21 days) by IV infusion. Post surgery: Participants received chemotherapy with fluorouracil 500-600 mg/m\^2, epirubicin 90-120 mg/m\^2, and cyclophosphamide 500-600 mg/m\^2 by IV infusion every 3 weeks from Cycles 5-7 (1 cycle = 21 days) followed by trastuzumab, 8 mg/kg loading dose in Cycle 8, followed by 6 mg/kg from Cycles 9-20 and placebo from Cycles 8-20 (1 cycle =21 days). | 110 |
| Total | 329 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Adjuvant Treatment | Physician Decision | 0 | 1 |
| Adjuvant Treatment | Pregnancy | 1 | 0 |
| Adjuvant Treatment | Recurrent Disease | 4 | 5 |
| Adjuvant Treatment | Withdrawal by Subject | 5 | 3 |
| Neoadjuvant Treatment | Adverse Event | 1 | 0 |
| Neoadjuvant Treatment | Death | 1 | 0 |
| Neoadjuvant Treatment | Did Not Receive Study Drug | 1 | 0 |
| Neoadjuvant Treatment | Physician Decision | 2 | 1 |
| Neoadjuvant Treatment | Progression of Disease | 2 | 3 |
| Neoadjuvant Treatment | Withdrawal by Subject | 4 | 3 |
| Treatment-Free Follow-Up | Death | 11 | 11 |
| Treatment-Free Follow-Up | Lost to Follow-up | 9 | 4 |
| Treatment-Free Follow-Up | Non-compliance | 0 | 1 |
| Treatment-Free Follow-Up | Reason Not Specified | 0 | 3 |
| Treatment-Free Follow-Up | Withdrawal by Subject | 13 | 3 |
Baseline characteristics
| Characteristic | Total | Placebo, Trastuzumab, and Chemotherapy | Pertuzumab, Trastuzumab, and Chemotherapy |
|---|---|---|---|
| Age, Continuous | 48.8 years STANDARD_DEVIATION 9.5 | 49.5 years STANDARD_DEVIATION 9.1 | 48.4 years STANDARD_DEVIATION 9.7 |
| Age, Customized 40-49 years old | 115 Participants | 40 Participants | 75 Participants |
| Age, Customized <40 years old | 58 Participants | 18 Participants | 40 Participants |
| Age, Customized 50-64 years old | 140 Participants | 44 Participants | 96 Participants |
| Age, Customized ≥65 years old | 16 Participants | 8 Participants | 8 Participants |
| Baseline LVEF value | 66.28 percentage points of LVEF STANDARD_DEVIATION 5.01 | 66.03 percentage points of LVEF STANDARD_DEVIATION 5.19 | 66.41 percentage points of LVEF STANDARD_DEVIATION 4.93 |
| Disease Category Early Stage | 229 Participants | 77 Participants | 152 Participants |
| Disease Category Locally Advanced | 100 Participants | 33 Participants | 67 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 329 Participants | 110 Participants | 219 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Hormone Receptor Status Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Positive | 170 Participants | 56 Participants | 114 Participants |
| Hormone Receptor Status Estrogen Receptor (ER) and Progesterone Receptor (PgR) Negative | 159 Participants | 54 Participants | 105 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 329 Participants | 110 Participants | 219 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Female | 329 Participants | 110 Participants | 219 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 12 / 218 | 11 / 110 |
| other Total, other adverse events | 218 / 218 | 108 / 110 |
| serious Total, serious adverse events | 37 / 218 | 15 / 110 |
Outcome results
Primary
Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC)
This tpCR was assessed by the IRC. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes after completion of neoadjuvant therapy and surgery (that is, ypT0/is, ypN0, in accordance with the current American Joint Committee on Cancer \[AJCC\] staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose tpCR assessment was missing or invalid were counted as not achieving tpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.
Time frame: At surgery (Cycle 4 Days 22-35)
Population: ITT population included all participants who were enrolled regardless of whether they received any study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC) | 39.3 percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC) | 21.8 percentage of participants |
p-value: 0.001495% CI: [6.89, 28.01]Cochran-Mantel-Haenszel
Secondary
Change From Baseline in LVEF Over Time
LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram (preferred) or MUGA scan. The same method was used throughout the study for each participant and preferably performed and evaluated by the same assessor. Here, we report the change from baseline in LVEF over time.
Time frame: Baseline; Day 1 of Cycles 2, 4, 5, 8, 11, and 20 (1 cycle = 21 days)
Population: Safety evaluable population included all participants who received at least one dose of study drugs. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at specified timepoints.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | Change From Baseline in LVEF Over Time | Cycle 2 Day 1 | -0.62 percentage points of LVEF |
| Pertuzumab, Trastuzumab, and Chemotherapy | Change From Baseline in LVEF Over Time | Cycle 4 Day 1 | -1.02 percentage points of LVEF |
| Pertuzumab, Trastuzumab, and Chemotherapy | Change From Baseline in LVEF Over Time | Cycle 5 Day 1 | -0.96 percentage points of LVEF |
| Pertuzumab, Trastuzumab, and Chemotherapy | Change From Baseline in LVEF Over Time | Cycle 8 Day 1 | -1.63 percentage points of LVEF |
| Pertuzumab, Trastuzumab, and Chemotherapy | Change From Baseline in LVEF Over Time | Cycle 11 Day 1 | -1.38 percentage points of LVEF |
| Pertuzumab, Trastuzumab, and Chemotherapy | Change From Baseline in LVEF Over Time | Cycle 20 Day 1 | -1.22 percentage points of LVEF |
| Placebo, Trastuzumab, and Chemotherapy | Change From Baseline in LVEF Over Time | Cycle 11 Day 1 | -0.65 percentage points of LVEF |
| Placebo, Trastuzumab, and Chemotherapy | Change From Baseline in LVEF Over Time | Cycle 2 Day 1 | 0.29 percentage points of LVEF |
| Placebo, Trastuzumab, and Chemotherapy | Change From Baseline in LVEF Over Time | Cycle 8 Day 1 | -1.18 percentage points of LVEF |
| Placebo, Trastuzumab, and Chemotherapy | Change From Baseline in LVEF Over Time | Cycle 4 Day 1 | 0.09 percentage points of LVEF |
| Placebo, Trastuzumab, and Chemotherapy | Change From Baseline in LVEF Over Time | Cycle 20 Day 1 | -1.18 percentage points of LVEF |
| Placebo, Trastuzumab, and Chemotherapy | Change From Baseline in LVEF Over Time | Cycle 5 Day 1 | 0.07 percentage points of LVEF |
Secondary
Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Disease-Free Survival (DFS) at 1, 3, and 5 Years
Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for DFS at 1, 3 and 5 years. DFS = time from first date of no disease (i.e., date of surgery) to first documentation of one of the following events: Disease recurrence (local, regional, distant, or contralateral) after surgery or death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year and then every 6 months thereafter, until disease progression or recurrence or until 5 years after randomization of the last participant, whichever occurred first. Participants were considered to be disease-free if they underwent surgery and no recurrence of disease was reported thereafter. Data from participants who did not have an event at analysis were censored as of the date they were last known to be alive and event-free.
Time frame: From surgery (Cycle 4: Days 22-35) to DFS event or date last known to be alive and event-free at 1, 3, and 5 years
Population: ITT population included all participants who were enrolled regardless of whether they received any study treatment. Overall number of participants analyzed are unique number of participants who underwent surgery. Number analyzed per timepoint are unique number of participants out of all the assessed participants who remain at risk for a DFS event at that timepoint. Different participants may have contributed data for each timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Disease-Free Survival (DFS) at 1, 3, and 5 Years | 1 Year | 97.55 estimate of percentage of participants |
| Pertuzumab, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Disease-Free Survival (DFS) at 1, 3, and 5 Years | 3 Years | 90.09 estimate of percentage of participants |
| Pertuzumab, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Disease-Free Survival (DFS) at 1, 3, and 5 Years | 5 Years | 85.99 estimate of percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Disease-Free Survival (DFS) at 1, 3, and 5 Years | 1 Year | 92.08 estimate of percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Disease-Free Survival (DFS) at 1, 3, and 5 Years | 3 Years | 81.10 estimate of percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Disease-Free Survival (DFS) at 1, 3, and 5 Years | 5 Years | 75.02 estimate of percentage of participants |
Comparison: Hazard Ratio for DFS Event in the Pertuzumab arm vs. Placebo armp-value: 0.01495% CI: [0.3, 0.88]Stratified log-rank
Comparison: Difference in DFS Event-Free Rates at 1 yearp-value: 0.059295% CI: [-11.15, 0.21]Z-test
Comparison: Difference in DFS Event-Free Rates at 3 yearsp-value: 0.042695% CI: [-17.69, -0.3]Z-test
Comparison: Difference in DFS Event-Free Rates at 5 yearsp-value: 0.027695% CI: [-20.73, -1.21]Z-test
Secondary
Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Event-Free Survival (EFS) at 1, 3, and 5 Years
Kaplan-Meier approach was used to estimate percentage of participants who were event-free for EFS at 1, 3 & 5 years. EFS=time from randomization to first documentation of one of the following events: PD (before surgery) as determined by investigator with RECIST v1.1. PD=at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum during the study (nadir) with inclusion of baseline. Any evidence of contralateral disease in situ was not identified as PD; Disease recurrence (local, regional, distant, or contralateral) after surgery; Death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year & then every 6 months thereafter, until disease progression/recurrence or until 5 years after randomization of last participant, whichever occurred first. Participants without an EFS event at time of analysis were censored as of the date they were last known to be alive & event-free.
Time frame: From Baseline to EFS event or date last known to be alive and event-free at 1, 3, and 5 years
Population: ITT population included all participants who were enrolled regardless of whether they received any study treatment. Number analyzed per timepoint are unique number of participants out of all the assessed participants who remain at risk for an EFS event at that timepoint. Different participants may have contributed data for each timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Event-Free Survival (EFS) at 1, 3, and 5 Years | 1 Year | 98.62 estimate of percentage of participants |
| Pertuzumab, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Event-Free Survival (EFS) at 1, 3, and 5 Years | 3 Years | 88.85 estimate of percentage of participants |
| Pertuzumab, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Event-Free Survival (EFS) at 1, 3, and 5 Years | 5 Years | 84.80 estimate of percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Event-Free Survival (EFS) at 1, 3, and 5 Years | 1 Year | 90.46 estimate of percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Event-Free Survival (EFS) at 1, 3, and 5 Years | 3 Years | 79.68 estimate of percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Event-Free Survival (EFS) at 1, 3, and 5 Years | 5 Years | 73.70 estimate of percentage of participants |
Comparison: Hazard Ratio for EFS Event in the Pertuzumab arm vs. Placebo armp-value: 0.01495% CI: [0.32, 0.89]Stratified log-rank
Comparison: Difference in EFS Event-Free Rates at 1 yearp-value: 0.006295% CI: [-14, -2.32]Z-test
Comparison: Difference in EFS Event-Free Rates at 3 yearsp-value: 0.042995% CI: [-18.05, -0.29]Z-test
Comparison: Difference in EFS Event-Free Rates at 5 Yearsp-value: 0.027495% CI: [-20.95, -1.24]Z-test
Secondary
Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1, 3, and 5 Years
Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for OS at 1, 3 and 5 years. OS was defined as the time from randomization to death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year and then every 6 months thereafter, until disease progression or recurrence or until 5 years after randomization of the last participant, whichever occurred first. Data from participants who were alive at the time of the analysis was censored as of the last date they were known to be alive.
Time frame: From Baseline to OS event or date last known to be alive at 1, 3, and 5 years
Population: ITT population included all participants who were enrolled regardless of whether they received any study treatment. Number analyzed per timepoint are unique number of participants out of all the assessed participants who remain at risk for an OS event at that timepoint. Different participants may have contributed data for each timepoint.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1, 3, and 5 Years | 1 Year | 99.54 estimate of percentage of participants |
| Pertuzumab, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1, 3, and 5 Years | 3 Years | 97.01 estimate of percentage of participants |
| Pertuzumab, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1, 3, and 5 Years | 5 Years | 93.86 estimate of percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1, 3, and 5 Years | 1 Year | 100.00 estimate of percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1, 3, and 5 Years | 3 Years | 90.99 estimate of percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1, 3, and 5 Years | 5 Years | 89.97 estimate of percentage of participants |
Comparison: Hazard Ratio for OS Event in the Pertuzumab arm vs. Placebo armp-value: 0.118195% CI: [0.23, 1.19]Stratified log-rank
Comparison: Difference in OS Event-Free Rates at 1 yearp-value: 0.316295% CI: [-0.44, 1.36]Z-test
Comparison: Difference in OS Event-Free Rates at 3 yearsp-value: 0.052995% CI: [-12.11, 0.08]Z-test
Comparison: Difference in OS Event-Free Rates at 5 yearsp-value: 0.261695% CI: [-10.69, 2.9]Z-test
Secondary
Maximum Change From Baseline in LVEF
LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram (preferred) or MUGA scan. The same method was used throughout the study for each participant and preferably performed and evaluated by the same assessor. Here, we report the maximum change from baseline in LVEF at any point during the study.
Time frame: Baseline; Day 1 of Cycles 2, 4, 5, 8, 11, and 20 (1 cycle = 21 days)
Population: Safety evaluable population included all participants who received at least one dose of study drugs and participants were grouped by the treatment they actually received. Overall number analyzed is the number of participants with data available for analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | Maximum Change From Baseline in LVEF | -6.55 percentage points of LVEF | Standard Deviation 5.22 |
| Placebo, Trastuzumab, and Chemotherapy | Maximum Change From Baseline in LVEF | -6.20 percentage points of LVEF | Standard Deviation 6.08 |
95% CI: [-1.62, 0.93]
Secondary
Percentage of Participants Who Experienced a Primary Cardiac Event
A primary cardiac event is defined as heart failure (New York Heart Association \[NYHA\] Class III or NYHA Class IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction points from baseline and to below 50%.
Time frame: From Baseline until end of study (up to 6 years)
Population: Safety evaluable population included all participants who received at least one dose of study drugs and participants were grouped by the treatment they actually received.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | Percentage of Participants Who Experienced a Primary Cardiac Event | 0 percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Percentage of Participants Who Experienced a Primary Cardiac Event | 0 percentage of participants |
Secondary
Percentage of Participants Who Experienced a Secondary Cardiac Event
A secondary cardiac event is defined as an asymptomatic or mildly symptomatic (NYHA Class II) drop in LVEF by multiple-gated acquisition (MUGA) scan or echocardiogram confirmed by a second LVEF assessment within approximately 3 weeks showing also a documented drop. A significant LVEF drop is defined as an absolute decrease of at least 10 points below the baseline measurement and to below 50%.
Time frame: From Baseline until end of study (up to 6 years)
Population: Safety evaluable population included all participants who received at least one dose of study drugs and participants were grouped by the treatment they actually received.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | Percentage of Participants Who Experienced a Secondary Cardiac Event | 0 percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Percentage of Participants Who Experienced a Secondary Cardiac Event | 0 percentage of participants |
Secondary
Percentage of Participants With an Objective Response (CR or PR) During Cycles 1-4, According to RECIST Version 1.1
An objective response was defined as the percentage of participants who achieved a CR or PR as the best tumor response during the neoadjuvant period (that is, during Cycles 1-4 prior to surgery), as determined by the investigator on the basis of RECIST version 1.1. CR=disappearance of all target lesions i.e., any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. No confirmation was required for objective response. Only participants with measurable disease at baseline were included in the analysis. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.
Time frame: At surgery (Cycle 4 Days 22-35)
Population: ITT population included all participants who were enrolled regardless of whether they received any study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | Percentage of Participants With an Objective Response (CR or PR) During Cycles 1-4, According to RECIST Version 1.1 | 88.6 percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Percentage of Participants With an Objective Response (CR or PR) During Cycles 1-4, According to RECIST Version 1.1 | 78.2 percentage of participants |
p-value: 0.012595% CI: [1.12, 19.69]Cochran-Mantel-Haenszel
Secondary
Percentage of Participants With at Least One Adverse Event (AE) During the Neoadjuvant Treatment Period
The percentage of participants who experienced at least one AE during the neoadjuvant period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. The neoadjuvant treatment period began after randomization upon receiving the first dose of any of the neoadjuvant study medications and ended before receiving the first dose of adjuvant study treatment. The duration of one treatment cycle is 21 days. The percentages have been rounded off to first decimal point.
Time frame: Baseline up to end of Cycle 4 (1 cycle = 21 days)
Population: Safety evaluable population included all participants who received at least one dose of neoadjuvant study treatment and participants were grouped by the treatment they actually received.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | Percentage of Participants With at Least One Adverse Event (AE) During the Neoadjuvant Treatment Period | 97.7 percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Percentage of Participants With at Least One Adverse Event (AE) During the Neoadjuvant Treatment Period | 96.4 percentage of participants |
Secondary
Percentage of Participants With at Least One Adverse Event During the Treatment-Free Follow-Up Period
The percentage of participants who experienced at least one adverse event during the treatment-free follow-up period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. The percentages have been rounded off to first decimal point.
Time frame: From end of overall study treatment until disease progression or until 5 years after randomization of the last patient, whichever occurred first (up to 6 years)
Population: Safety evaluable population included all participants who received at least one dose of study drugs and participants were grouped by the treatment they actually received.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | Percentage of Participants With at Least One Adverse Event During the Treatment-Free Follow-Up Period | 6.0 percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Percentage of Participants With at Least One Adverse Event During the Treatment-Free Follow-Up Period | 7.3 percentage of participants |
Secondary
Percentage of Participants With at Least One AE During the Adjuvant Treatment Period
Percentage of participants who experienced at least one adverse event during the adjuvant period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. Adjuvant treatment period began after primary surgery, upon receiving the first dose of any of the adjuvant study medications. It ended 42 days after last dose of adjuvant study treatment upon treatment completion or discontinuation. 1 Cycle=21 days. The percentages have been rounded off to first decimal point.
Time frame: From Cycle 5 (1 cycle = 21 days) up to 42 days after the last dose in Cycle 20 Day 1 (approximately 1 year)
Population: Safety evaluable population included all participants who received at least one dose of adjuvant study treatment and participants were grouped by the treatment they actually received. Overall number analyzed is the number of participants with data available for analysis.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | Percentage of Participants With at Least One AE During the Adjuvant Treatment Period | 98.1 percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Percentage of Participants With at Least One AE During the Adjuvant Treatment Period | 98.1 percentage of participants |
Secondary
Percentage of Participants With bpCR as Assessed by the Local Pathologist
This bpCR was assessed by the local pathologist. bpCR was defined as the absence of any residual invasive cancer on the hematoxylin and eosin evaluation of the resected breast specimen after completion of neoadjuvant therapy and surgery (that is, ypT0/is in accordance with current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose bpCR assessment was missing or invalid were counted as not achieving bpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.
Time frame: At surgery (Cycle 4 Days 22-35)
Population: ITT population included all participants who were enrolled regardless of whether they received any study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | Percentage of Participants With bpCR as Assessed by the Local Pathologist | 41.6 percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Percentage of Participants With bpCR as Assessed by the Local Pathologist | 22.7 percentage of participants |
p-value: 0.000695% CI: [8.14, 29.51]Cochran-Mantel-Haenszel
Secondary
Percentage of Participants With Breast Pathologic Complete Response (bpCR), Defined as ypT0/is According to the AJCC Staging System as Assessed by the IRC
This bpCR was assessed by the IRC. bpCR was defined as the absence of any residual invasive cancer on the hematoxylin and eosin evaluation of the resected breast specimen after completion of neoadjuvant therapy and surgery (that is, ypT0/is, in accordance with current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose bpCR assessment was missing or invalid were counted as not achieving bpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.
Time frame: At surgery (Cycle 4 Days 22-35)
Population: ITT population included all participants who were enrolled regardless of whether they received any study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | Percentage of Participants With Breast Pathologic Complete Response (bpCR), Defined as ypT0/is According to the AJCC Staging System as Assessed by the IRC | 42.0 percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Percentage of Participants With Breast Pathologic Complete Response (bpCR), Defined as ypT0/is According to the AJCC Staging System as Assessed by the IRC | 23.6 percentage of participants |
p-value: 0.00195% CI: [7.6, 29.15]Cochran-Mantel-Haenszel
Secondary
Percentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Clinical responses that include percentage of participants with a CR, PR, SD, or PD were determined by investigator during Cycles 1-4 (prior to surgery) on basis of RECIST version 1.1. CR=disappearance of all target lesions i.e., any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum during the study. PD=at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (nadir) with inclusion of baseline. Only participants with measurable disease at baseline were included in the analysis. 1 Cycle=21 days. The percentages have been rounded off to first decimal point.
Time frame: At surgery (Cycle 4 Days 22-35)
Population: ITT population included all participants who were enrolled regardless of whether they received any study treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | Percentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Partial Response | 77.6 percentage of participants |
| Pertuzumab, Trastuzumab, and Chemotherapy | Percentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Progressive Disease | 0.5 percentage of participants |
| Pertuzumab, Trastuzumab, and Chemotherapy | Percentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Stable Disease | 8.2 percentage of participants |
| Pertuzumab, Trastuzumab, and Chemotherapy | Percentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Missing or Unevaluable | 2.7 percentage of participants |
| Pertuzumab, Trastuzumab, and Chemotherapy | Percentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Complete Response | 11.0 percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Percentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Missing or Unevaluable | 0.9 percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Percentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Complete Response | 10.0 percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Percentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Partial Response | 68.2 percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Percentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Stable Disease | 19.1 percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Percentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Progressive Disease | 1.8 percentage of participants |
Secondary
Percentage of Participants With tpCR as Assessed by the Local Pathologist
This tpCR was assessed by the local pathologist. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes after completion of neoadjuvant therapy and surgery (that is, ypT0/is, ypN0, in accordance with the current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose tpCR assessment was missing or invalid were counted as not achieving tpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.
Time frame: At surgery (Cycle 4 Days 22-35)
Population: ITT population included all participants who were enrolled regardless of whether they received any study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pertuzumab, Trastuzumab, and Chemotherapy | Percentage of Participants With tpCR as Assessed by the Local Pathologist | 39.3 percentage of participants |
| Placebo, Trastuzumab, and Chemotherapy | Percentage of Participants With tpCR as Assessed by the Local Pathologist | 20.9 percentage of participants |
p-value: 0.000895% CI: [7.89, 28.83]Cochran-Mantel-Haenszel